VACC - Vaccitech to receive milestone and royalty payment of $15M for COVID-19 vaccine

Vaccitech (NASDAQ:VACC) said it had been notified that it would receive $15M as its share of milestone and royalty payments from AstraZeneca’s sales of Vaxzevria vaccine during the fourth quarter of 2021. U.K. biopharma Vaccitech and Oxford University co-created the COVID-19 vaccine, licensing the drug’s actual manufacturing and distribution to AstraZeneca. Under the licensing agreement, Vaccitech is entitled to receive about 24% of payments received by Oxford University Innovation from AstraZeneca. The company said AstraZeneca and its contract manufacturing partners have supplied more than 2.6 billion doses of the vaccine. The company in January said it had begun dozing in phase 1/2a study of VTP-600 to treat lung cancer.

For further details see:

Vaccitech to receive milestone and royalty payment of $15M for COVID-19 vaccine